# AstraZeneca plc Lynparza approved in Japan for 1st-line maintenance therapy

- Link: https://www.directorstalkinterviews.com/astrazeneca-plc-lynparza-approved-in-japan-for-1st-line-maintenance-therapy/412785465
- Published: 2019-06-19T07:30:17+01:00
- Author: Amilia Stone

**[AstraZeneca plc](https://www.directorstalkinterviews.com/ftse-company/astrazeneca/azn.l)**(
[LON:AZN](https://www.directorstalkinterviews.com/ftse-company/astrazeneca/azn.l))
and MSD Inc., Kenilworth, N.J., US today announced that Lynparza has been approved
in Japan as a maintenance treatment after 1st-line chemotherapy in patients with
BRCA-mutated advanced ovarian cancer, as detected by an approved companion diagnostic
test.

The approval by the Japanese Ministry of Health, Labour and Welfare was based on
data from the pivotal Phase III SOLO-1 trial which tested _Lynparza_ as maintenance
monotherapy compared with placebo in patients with BRCAm advanced ovarian cancer
following 1st-line platinum-based chemotherapy.

> **Dave Fredrickson, Executive Vice President, Oncology Business Unit, said**: “
> This approval in Japan is a critical advance for women with ovarian cancer and
> a BRCA mutation. The goals of front-line therapy are long-term remission or a 
> cure, yet currently 70% of patients relapse within three years of initial treatment.
> The progression-free survival benefit of _Lynparza_ observed in SOLO-1 represents
> a major step forward in our ambition to transform patient outcomes.”

> **Roy Baynes, Senior Vice President and Head of Global Clinical Development, Chief
> Medical Officer, MSD Research Laboratories, said**: “Advances in understanding
> the role of BRCA mutations and PARP inhibition have fundamentally changed how 
> physicians can treat this aggressive type of cancer. With the approval of this
> new indication, patients in Japan with BRCA-mutated advanced ovarian cancer who
> respond to chemotherapy will have the opportunity to benefit from _Lynparza _in
> the 1st-line maintenance setting.”

Results for the SOLO-1 trial announced in October 2018 showed at 40.7 months of 
follow-up the median time of progression for patients treated with _Lynparza_ had
not yet been reached vs. 13.8 months for those on placebo (HR 0.30 [95% CI, 0.23-
0.41], p<0.001).

Lynparza is the only PARP inhibitor approved in Japan. AstraZeneca and MSD are exploring
additional trials in ovarian cancer, including the ongoing Phase III PAOLA-1 trial,
which is testing _Lynparza_ in combination with bevacizumab as a 1st-line maintenance
treatment for women with newly-diagnosed, advanced, stage IIIB-IV high grade serous
or endometrioid ovarian cancer, regardless of BRCA status.

The Japanese approval follows European Commission marketing authorisation announced
in June 2019. Interactions with regulatory authorities in the rest of the world 
are ongoing.

**About SOLO-1**

SOLO-1 was a Phase III, randomised, double-blinded, placebo-controlled, multi-centre
trial to evaluate the efficacy and safety of _Lynparza_ tablets (300mg twice daily)
as a maintenance monotherapy compared with placebo in patients with BRCAm advanced
ovarian cancer following first-line platinum-based chemotherapy. The trial randomised
391 patients with a deleterious or suspected deleterious germline or somatic BRCA1
or BRCA2 mutation who were in clinical complete or partial response following platinum-
based chemotherapy.

Patients were randomised (2:1) to receive _Lynparza_ or placebo for up to two years
or until disease progression. Patients who had a partial response at two years were
permitted to stay on therapy at the investigator’s discretion. The primary endpoint
was progression-free survival (PFS) and key secondary endpoints included time to
second disease progression or death, time to first subsequent treatment and overall
survival.

The data were presented on 21 October 2018, at the Presidential Symposium of the
ESMO 2018 Congress in Munich, Germany and published simultaneously online in _The
New England Journal of Medicine._ 

**Summary of PFS**^(i,ii)

|   | _Lynparza_ (n=260) | Placebo (n=131) | 
| Number of patients with event (%)^(iii) | 102 (39) | 96 (73) | 
| Median PFS (in months) | Not reached | 13.8 | 
| Hazard ratio (95% CI) | 0.30 (0.23-0.41) | 
| P-value | p<0.001 |

^(i Investigator-assessed.)

^(ii Median (interquartile range) duration of follow-up 40.7 months (34.9-42.9) 
for _Lynparza_ and 41.2 months (32.2-41.6) for placebo.)

^(iii Analysis was done at 50.6% maturity.)

The SOLO-1 safety profile was in line with that observed in prior clinical trials.
The most common adverse events (AEs) ≥ 20% were nausea (77%), fatigue (63%), vomiting(
40%), anaemia (39%) and diarrhoea (34%). The most common ≥ Grade 3 AEs were anaemia(
22%) and neutropenia (9%). Some 71% of patients on _Lynparza_ remained on the recommended
starting dose. Additionally, 88% of patients on _Lynparza_ continued treatment without
an AE-related discontinuation.

**About ovarian cancer**

Ovarian cancer is a leading cause of cancer deaths in women worldwide. Most women
diagnosed with Stage IV ovarian cancer have a five-year survival rate of approximately
17%.^(1) In 2018, there were nearly 300,000 new cases diagnosed and around 185,000
deaths.^(2) For newly-diagnosed advanced ovarian cancer, the primary aim of treatment
is to delay progression of the disease for as long as possible and maintain the 
patient’s quality of life with the intent of achieving complete remission or cure.
^(3,4,5,6)

**About BRCA mutations**

BRCA1 and BRCA2 are human genes that produce proteins responsible for repairing 
damaged DNA and play an important role in maintaining the genetic stability of cells.
When either of these genes is mutated, or altered, such that its protein product
either is not made or does not function correctly, DNA damage may not be repaired
properly, and cells become unstable. As a result, cells are more likely to develop
additional genetic alterations that can lead to cancer.

**About **_**Lynparza**_

_Lynparza_ (olaparib) is a first-in-class PARP inhibitor and the first targeted 
treatment to block DNA damage response (DDR) in cells/tumours harbouring a deficiency
in homologous recombination repair (HRR), such as mutations in BRCA1 and/or BRCA2.
Inhibition of PARP with _Lynparza_ leads to the trapping of PARP bound to DNA single-
strand breaks, stalling of replication forks, their collapse and the generation 
of DNA double-strand breaks and cancer cell death. _Lynparza_ is being tested in
a range of PARP-dependent tumour types with defects and dependencies in the DDR.

_Lynparza _is currently approved in over 60 countries, including those in the EU,
for the maintenance treatment of platinum-sensitive relapsed ovarian cancer regardless
of BRCA status. It is approved in the EU, US, Canada, Japan and Brazil as 1st-line
maintenance treatment of BRCAm advanced ovarian cancer following response to platinum-
based chemotherapy. It is also approved in nearly 40 countries for germline BRCAm
HER2-negative metastatic breast cancer previously treated with chemotherapy. Regulatory
reviews are underway in other jurisdictions for ovarian, breast and pancreatic cancers.

_Lynparza_ has the broadest and most advanced clinical trial development programme
of any PARP inhibitor, and AstraZeneca and MSD are working together to understand
how it may affect multiple PARP-dependent tumours as a monotherapy and in combination
across multiple cancer types. _Lynparza_ is the foundation of AstraZeneca’s industry-
leading portfolio of potential new medicines targeting DDR mechanisms in cancer 
cells.

**About the AstraZeneca and MSD strategic oncology collaboration**

In July 2017, AstraZeneca and Merck & Co., Inc., Kenilworth, NJ, US, known as MSD
outside the United States and Canada, announced a global strategic oncology collaboration
to co-develop and co-commercialise _Lynparza_, the world’s first PARP inhibitor,
and potential new medicine selumetinib, a MEK inhibitor, for multiple cancer types.
Working together, the companies will develop _Lynparza_ and selumetinib in combination
with other potential new medicines and as monotherapies. Independently, the companies
will develop _Lynparza_ and selumetinib in combination with their respective PD-
L1 and PD-1 medicines.

**About AstraZeneca in Oncology**

AstraZeneca has a deep-rooted heritage in Oncology and offers a quickly-growing 
portfolio of new medicines that has the potential to transform patients’ lives and
the Company’s future. With at least six new medicines to be launched between 2014
and 2020, and a broad pipeline of small molecules and biologics in development, 
we are committed to advance Oncology as one of AstraZeneca’s four Growth Platforms
focused on lung, ovarian, breast and blood cancers. In addition to our core capabilities,
we actively pursue innovative partnerships and investments that accelerate the delivery
of our strategy, as illustrated by our investment in Acerta Pharma in haematology.

By harnessing the power of four scientific platforms – Immuno-Oncology, Tumour Drivers
and Resistance, DNA Damage Response and Antibody Drug Conjugates – and by championing
the development of personalised combinations, AstraZeneca has the vision to redefine
cancer treatment and one day eliminate cancer as a cause of death.

Share on:
